Editor's Note: From October 19-20, 2024, the first stop of the "St. Gallen Breast Cancer Conference China Tour" was held in Nanjing. This series of conferences is organized by the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), with support from the Beijing Xisike Clinical Oncology Research Foundation, the Beijing Kexin Medical Development Foundation, and the Jiangsu Anti-Cancer Association. It is hosted by Jiangsu Provincial People's Hospital. SGBCC President, Prof. Michael Gnant, personally attended the event, facilitating the exchange of the latest advancements between European, Japanese, and Chinese breast cancer experts. Prof. Zefei Jiang, the President-Elect of CSCO and a member of the St. Gallen Breast Cancer International Consensus Panel, shared his insights and expressed his expectations for future cooperation between SGBCC and CSCO.

Prof. Zefei Jiang :“I warmly welcome everyone to the St. Gallen Breast Cancer Conference (SGBCC) China Tour and extend my sincere gratitude to Prof. Yongmei Yin for her kind invitation.

At this grand event, we are privileged to host discussions between European, Japanese, and Chinese experts, sharing insights from the St. Gallen International Expert Consensus and academic progress. SGBCC President Prof. Michael Gnant will personally attend the meetings in Nanjing, Shanghai, Xi’an, and Beijing to share the history and key future discussion points of the St. Gallen International Expert Consensus. Scholars from Europe, Japan, and China will collaboratively explore recent academic developments and discuss key updates for the upcoming St. Gallen International Expert Consensus.

Since 2011, Chinese experts have gradually joined the SGBCC chairing committee. I am honored to represent China alongside Academician Binghe Xu, Prof. Zhimin Shao, Prof. Yongmei Yin, and scholars from Taiwan in the 2025 SGBCC and contribute to shaping the St. Gallen International Expert Consensus. What fills me with even more pride is that next year, we will organize 100 Chinese doctors to attend the SGBCC in Vienna. The conference will feature a dedicated China session, where international and Chinese experts will jointly share field advancements and engage in broader academic exchanges. Prof. Michael Gnant has also promised to lead the SGBCC delegation to the CSCO Breast Cancer (CSCO BC) Annual Meeting in April next year to further strengthen SGBCC-CSCO collaboration.

For CSCO, newly elected President Academician Jinming Yu will actively lead CSCO towards greater international cooperation. He aims to propel CSCO onto the global stage, fostering deeper exchanges with international societies and promoting the adoption of advanced concepts and treatment techniques to advance breast cancer and oncology care in China.

Breast cancer treatment has now reached an era of refined precision therapy and diversified treatment modalities. During recent academic exchanges, experts have repeatedly emphasized the rapid advancements in several areas:

• Hormone Receptor-Positive Breast Cancer: The development of high-quality domestic products has been flourishing.
• HER2-Targeted Therapy: We have witnessed tremendous progress, moving from a starting point of scarcity to highly refined strategies, including from neoadjuvant to advanced stages, single-target to dual-target, and from small molecules to antibody-drug conjugates (ADCs).
• Triple-Negative Breast Cancer (TNBC): Significant advancements have been achieved in chemotherapy, combination chemotherapy, and immunotherapy.
• Translational Medicine: Domestic elite teams have made strides in translational medicine, greatly promoting clinical research and solving many clinical problems.

As members of CSCO, we are enthusiastic about participating in such academic collaborations and exchanges. We are particularly eager for more professional medical media to join these efforts, disseminating scientifically accurate treatment information and conveying the valuable scientific contributions of Chinese scholars. By doing so, we can better strengthen international exchanges and sector cooperation, amplifying China’s voice and making greater contributions to the health sector.”

Prof. Zefei Jiang:

• Position: President-Elect of CSCO, St. Gallen Breast Cancer International Consensus Panel Member
• Roles: Leading various international and national academic committees, dedicated to advancing breast cancer treatment standards in China.

This collaboration is poised to further elevate China’s standing in global breast cancer research and treatment, building on the strong foundations laid by joint efforts from both Chinese and international experts.